Research and Markets: Novo Nordisk Holds a Leading Position in Haemostasis Management, Growth Hormone Therapy & Hormone Replacement Therapy.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c43260) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: Novo Nordisk Pharmaceutical Company Intelligence Report to their offering. Pharmaceutical Company Intelligence Reports provide a full review of the companys activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 40 Company Intelligence Reports are currently available. Summary Novo Nordisk is a biotech-based healthcare company with a broad diabetes product portfolio. In addition, it has a leading position in haemostasis hemostasis, haemostasis the stoppage of bleeding or cessation of the circulation of the blood; stagnation of the blood in a part of the body. Also hemostasia, haemostasia. See also: Blood and Blood Vessels Noun 1. management, growth hormone therapy and hormone replacement therapy Hormone Replacement Therapy Definition Hormone replacement therapy (HRT) is the use of synthetic or natural female hormones to make up for the decline or lack of natural hormones produced in a woman's body. . It is currently expanding into the new therapeutic areas of cancer and inflammation. Current Growth Drivers The insulin analogues (+62 per cent), particularly Levemir, and NovoSeven (+16 per cent). Key Late-Stage Products Liraglutide, a long-acting derivative of the natural hormone glucagon-like peptide-1 (GLP-1), is in Phase III trials. The drug only reduces blood glucose when it is too high, thus eliminating the threat of hypoglycaemia Noun 1. hypoglycaemia - abnormally low blood sugar usually resulting from excessive insulin or a poor diet hypoglycemia insulin reaction, insulin shock - hypoglycemia produced by excessive insulin in the system causing coma . Key Early-Stage Products Within the new therapeutic area of oncology, Novo Nordisk is developing interleukin-21 (IL-21) in Phase I trials for cancer and malignant melanoma. This novel cytokine Cytokine Any of a group of soluble proteins that are released by a cell to send messages which are delivered to the same cell (autocrine), an adjacent cell (paracrine), or a distant cell (endocrine). has potent biological activity in regulating key classes of immune cells, including cytotoxic T-cells and NK cells, which are thought to play key roles in eliminating malignant and infected cells from the body. Companies Mentioned * Aradigm Corporation * Argos Therapeutics * BioStratum Incorporated * BioVisioN AG * Cephalon * GlaxoSmithKline * G2 Inflammation Pty Ltd * Innate Pharma SAS (1) (SAS Institute Inc., Cary, NC, www.sas.com) A software company that specializes in data warehousing and decision support software based on the SAS System. Founded in 1976, SAS is one of the world's largest privately held software companies. See SAS System. * Medarex Inc * Morphotek Inc * Nastech Pharmaceutical * Neose Technologies Inc * Sangamo BioSciences Inc * Sapphire Therapeutics Inc * Scios Inc * Takeda * Transition Therapeutics Inc * TransTech Pharma (TTP TTP (thymidine triphosphate): see thymine. ) * ZymoGenetics Inc For more information visit http://www.researchandmarkets.com/reports/c43260. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion